ホーム › 多発性骨髄腫 › アリゾナ州 › Phoenix
Phoenix、AZにおける多発性骨髄腫の臨床試験
Phoenixとその周辺地域（約30マイル以内）の拠点で、多発性骨髄腫に関する16件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
被験者募集中第3相
- Mayo Clinic 1, Phoenix
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
被験者募集中第3相
- Mayo Clinic Phoenix, Phoenix
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
被験者募集中第3相
- Mayo Clinic Phoenix, Mayo Clinic Building, Phoenix
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
被験者募集中第4相
- Mayo Clinic Cancer Center-Scottsdale, Phoenix
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
被験者募集中第2相
- Cancer Treatment Centers of America-Phoenix, Phoenix
Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
被験者募集中第1相
- Mayo Clinic Hospital in Arizona, Phoenix
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
被験者募集中第1相
- Mayo Clinic Arizona, Phoenix
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
被験者募集中第3相
- Cancer Center at Saint Joseph's, Phoenix
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
被験者募集中第1/2相
- Research Site, Phoenix
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
被験者募集中第3相
- Research Site, Phoenix
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
被験者募集中第2相
- Mayo Clinic - Arizona, Phoenix
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
被験者募集中第1相
- Mayo Clinic in Arizona - Phoenix, Phoenix
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
被験者募集中第1相
- Mayo Clinic Arizona /ID# 251405, Phoenix
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
被験者募集中第3相
- Cancer Center at Saint Joseph's, Phoenix
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
被験者募集中第3相
- Banner University Medical Center Tucson, University of Arizona, Phoenix
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
被験者募集中第3相
- GSK Investigational Site, Phoenix
他の都市における多発性骨髄腫の試験
- New York City, NY60件の研究
- Boston, MA42件の研究
- Atlanta, GA41件の研究
- Houston, TX38件の研究
- Durham, NC37件の研究
- Nashville, TN32件の研究
- Denver, CO27件の研究
- Rochester, MN24件の研究
- St. Louis, MO24件の研究
- Columbus, OH24件の研究
- Baldwin Park, CA23件の研究
- Chicago, IL22件の研究
Phoenixにおける他の研究
- 乳がん25件の研究
- 大腸癌25件の研究
- 肥満症22件の研究
- 非小細胞肺癌20件の研究
- 転移性癌20件の研究
- 心不全18件の研究
- 前立腺がん17件の研究
- がん（全種類）17件の研究
- 膵臓がん16件の研究
- 心血管疾患16件の研究
- アルツハイマー病15件の研究
- 過体重15件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。